DOCSLIB.ORG

(ACE2) Gene Therapy Improves Glycemic Control in Diabetic Mice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(ACE2) Gene Therapy Improves Glycemic Control in Diabetic Mice Diabetes Publish Ahead of Print, published online August 25, 2010 ACE2 and diabetes Angiotensin-I Converting Enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Sharell M. Bindom, Chetan P. Hans, Huijing Xia, A. Hamid Boulares and Eric Lazartigues Department of Pharmacology & Experimental Therapeutics and Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA. Running title: ACE2 and diabetes Correspondence: Eric Lazartigues, PhD E-mail address: [email protected] Submitted 25 May 2009 and accepted 8 July 2010 Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org. 1 Copyright American Diabetes Association, Inc., 2010 ACE2 and diabetes Objective—Several clinical studies have shown the benefits of renin-angiotensin system (RAS) blockade in the development of diabetes and a local RAS has been identified in pancreatic islets. Angiotensin-I Converting Enzyme (ACE) 2, a new component of the RAS has been identified in the pancreas but its role in β-cells function remains unknown. Using 8 and 16-week old obese diabetic (db/db) mice, we examined the ability of ACE2 to alter pancreatic β-cell function and thereby modulate hyperglycemia. Research design and methods—Both db/db and non-diabetic lean control (db/m) mice were infected with an adenovirus expressing human ACE2 (Ad-hACE2-eGFP) or the control virus (Ad-eGFP), via injection into the pancreas. Glycemia and β-cell function were assessed 1 week later, at the peak of viral expression. Results—In 8-week old db/db mice, Ad-hACE2-eGFP significantly improved fasting glycemia, enhanced intra-peritoneal (IP) glucose tolerance, increased islet insulin content and β-cell proliferation and reduced β-cell apoptosis when compared to Ad-eGFP. ACE2 over-expression had no effect on insulin sensitivity in comparison to Ad-eGFP treatment in diabetic mice. Angiotensin-(1-7) receptor blockade by D-Ala7-Ang-(1-7) prevented the ACE2-mediated improvements in IP glucose tolerance, glycemia and islet function and also impaired insulin sensitivity in both Ad-hACE2-eGFP and Ad-eGFP treated db/db mice. D-Ala7-Ang-(1-7) had no effect on db/m mice. In 16-week old diabetic mice, Ad-hACE2-eGFP treatment improved fasting blood glucose but had no effect on any of the other parameters. Conclusions—These findings identify ACE2 as a novel target for the prevention of β-cell dysfunction and apoptosis occurring in type 2 diabetes. n addition to the systemic renin- receptor (AT1R) axis of the RAS leads to a angiotensin system (RAS) that regulates cascade of events implicated in the Iblood pressure, the concept of a tissue development of β-cell dysfunction, including: RAS, modulating local organ function, is now increased islet fibrosis (6), oxidative stress well recognized. Accordingly, most organs (7,8) and inhibition of pro-insulin express a tissue RAS, capable of locally biosynthesis, first phase and glucose- producing Angiotensin (Ang)-II (1). A responsive insulin secretion (3,5,9). complete tissue RAS has been identified in Moreover, several studies have demonstrated the endocrine and exocrine pancreas and the the effectiveness of RAS blockade at expression of its various components has been improving islet morphology and function and demonstrated in the islets of Langerhans (2- reducing islet oxidative stress (3,5,8,10) (for 4). While the role of the islet RAS is not review see (11)). Recently, Angiotensin completely understood, recent data suggest Converting Enzyme (ACE) 2, a captopril- that it may be important in β-cell homeostasis insensitive ACE homologue, was identified and function. Indeed, it has been shown to be (12,13) and shown to cleave Ang-II into the involved in the regulation of glucose biologically active peptide Ang-(1-7) (13). stimulated-insulin secretion, insulin synthesis Ang-(1-7) properties are mediated by the G- (3), as well as islet blood flow (5). protein-coupled receptor Mas (14), causing Hyperactivity of the ACE/Ang-II/AT1 vasodilation, inhibition of fibrosis (15), 2 ACE2 and diabetes stimulation of PGE2 (16) and NO releases pancreas (n=8/group). The adenovirus was (17). The ACE2/Ang-(1-7)/Mas axis is delivered in five 20 μl injections along the hypothesized to act as a negative regulator for body of the pancreas (Fig. 2A). For a subset of the RAS. Recent data indicate that this animals, D-Ala7-Ang-(1-7), an Ang-(1-7) alternate pathway may play a compensatory receptor antagonist, was infused (600 role in the development of type 2 diabetes ng/kg/min/7 days) using mini-osmotic pumps mellitus (T2DM). ACE2 protein is elevated in (Durect, Cuppertino, CA) implanted the islets of Zucker fatty diabetic rats (10) and subcutaneously (SC) at the time of virus ACE2 knockout (ACE2-/y) mice exhibit injection. All procedures were approved by progressive impairments in glucose tolerance the Animal Use and Care Committee at and reduced first-phase insulin secretion (18). Louisiana State University Health Sciences Loss of first phase insulin secretion, an Center, New Orleans. indicator of pancreatic β-cell dysfunction, is Determination of ACE2 expression and considered to be one of the earliest insults in activity. To prevent protein degradation, T2DM and is evident before the onset of pancreata were first incubated in RNAlater® impaired glucose tolerance (19). Defects in stabilization solution and stored at -80 °C. insulin sensitivity, glucose tolerance and Western blotting for ACE2 expression and glucose uptake exhibited by Mas receptor ACE2 activity assays were performed as knockout mice (20) further implicate the loss described previously (21). of Ang-(1-7) signaling in the development of Measurements of physiological parameters. T2DM and metabolic syndrome. We To assess glucose metabolism in db/db mice, hypothesized that ACE2 overexpression may we performed an intra-peritoneal (IP) glucose ameliorate glucose homeostasis in diabetic tolerance test, where fasted (12 hr) animals mice and prevent the development of were weighed and a bolus IP injection of pancreatic β-cell dysfunction. Using leptin glucose (2 g/kg) was administered to receptor-deficient obese diabetic (db/db) conscious mice. Blood was drawn from the mice, we report that ACE2 overexpression catheterized tail vein and analyzed at 0, 15, reduced glycemia and increased islet insulin 30, 60 and 120 min after glucose content through Ang-(1-7)-mediated administration, using a glucometer (Accu- pathways. Our data confirm the pivotal role of check® Aviva, Roche, Mannheim, Germany). this peptide in the pancreas and establish To determine first phase insulin secretion, ACE2 as a new target for the treatment of fasted mice were anesthetized with isoflurane T2DM. and given a bolus of glucose (1g/kg IP). Blood samples (50 μl) were collected from a RESEARCH DESIGN AND METHODS catheterized carotid artery at 0, 2, 5 and 10 Animals and treatments. Three, 7 and 15- min following glucose administration. Plasma week old male db/db and non-diabetic (db/m) insulin was then measured using ELISA mice (BKS.Cg-m +/+ Leprdb/J, Jackson (Crystal Chem, Downers Grove, IL). Laboratories, Bar Harbor, ME) were infected Insulin sensitivity was analyzed following 1 with an adenovirus coding for human ACE2 hr fast and mice injected SC with human (hACE2), upstream of an enhanced green recombinant insulin (0.3 U/kg; Sigma, St fluorescent protein (eGFP) reporter gene (Ad- Louis, MO). Blood glucose was measured at hACE2-eGFP) or with the eGFP virus alone 0, 15, 30, 60 and 120 min following injection. (Ad-eGFP) (21) by direct injection (5x107 Fasting blood glucose, glucose tolerance and particle forming units (pfu) in a total volume insulin tolerance were measured prior and 7 of 100 μl of 0.9% w/v saline) into the days after adenovirus administration. The 3 ACE2 and diabetes animals were then sacrificed, the pancreas was developed using DAB. Images capture was removed and rapidly divided, with one was performed using a Nikon eclipse E600 half being fixed in 10% formalin in phosphate light microscope. All images were quantified buffered saline (PBS) and the other half using image pro plus software (Media frozen in liquid nitrogen. Cybernetics, Bethesda, MD). For a semi- Immunohistochemistry. Pancreas sections (5 quantitative assessment of islet insulin, mouse µm) were prepared from 10% formalin-fixed, ACE2 (mACE2) and hACE2, staining per paraffin-embedded tissue. For antigen islet (n=16-20/group) area was used to unmasking, sections were incubated in a quantify protein content from citrate buffer solution (100 mM citric acid, immunohistochemistry (10). For PCNA and 100 mM sodium citrate, Sigma) for 13 min at TUNEL staining, positive cells per islet were 100 °C. Following washes, sections were counted. To assess pancreatic β-cell mass, the incubated for 1 hr at room temperature in a mean density of islet insulin staining was blocking solution containing 5% bovine multiplied by the mean islet area per serum albumin in PBST. Sections were pancreatic section, adjusted for wet organ incubated with an anti-insulin primary weight per animal (six sections per organ) antibody (1:100; Abcam, Cambridge, MA) for (10). 4 hr at 4 °C, followed by incubation with Statistical analysis. Data are expressed as biotinylated anti-guinea pig secondary mean ±SEM. Data were analyzed by antibody (1:200; Vector Laboratories, Student’s t test or two-way ANOVA Burlingame, CA) for 1 hr at room (Bonferroni post hoc tests to compare temperature.
Load more

Recommended publications
  • The Direct Effects of the Angiotensin-Converting Enzyme
    European Journal of Endocrinology (2006) 154 355–361 ISSN 0804-4643 EXPERIMENTAL STUDY The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets Roberto Lupi, Silvia Del Guerra, Marco Bugliani, Ugo Boggi1, Franco Mosca1, Scilla Torri, Stefano Del Prato and Piero Marchetti Metabolic Unit, Department of Endocrinology and Metabolism, University of Pisa, Ospedale Cisanello, via Paradisa 2, 56100 Pisa, Italy and 1Transplant Unit, Department of Oncology, University of Pisa, Pisa, Italy, Menarini Ricerche SpA, Florence, Italy (Correspondence should be addressed to P Marchetti; Email: [email protected]) Abstract Objective: Data from prospective studies suggest a significant reduction in the risk of new diabetes from drug therapies containing angiotensin-converting enzyme (ACE) inhibitors. Since the renin–angio- tensin system (RAS) has been found locally in several tissues and cells, including pancreatic islets, we hypothesized that the positive metabolic effects of ACE inhibitors may be due to a beneficial action of these compounds on insulin-secreting b-cells. Design and methods: Isolated human pancreatic islets were studied after 24 h of incubation with 22.2 mmol/l glucose, with or without the presence in the incubation medium of 0.5–6.0 mmol/l zofe- noprilat or enalaprilat, ACE inhibitor drugs which differ by the presence of a sulphydryl or a carboxyl group in their structural formula. Functional and molecular studies were then performed to assess insulin secretion, redox balance, mRNA and protein expression. Results: Angiotensinogen, ACE and angiotensin type 1 receptor mRNA expression increased in islets cultured in high glucose; this was similarly prevented by the presence of either ACE inhibitor.
    [Show full text]
  • A Global Review on Short Peptides: Frontiers and Perspectives †
    molecules Review A Global Review on Short Peptides: Frontiers and Perspectives † Vasso Apostolopoulos 1 , Joanna Bojarska 2,* , Tsun-Thai Chai 3 , Sherif Elnagdy 4 , Krzysztof Kaczmarek 5 , John Matsoukas 1,6,7, Roger New 8,9, Keykavous Parang 10 , Octavio Paredes Lopez 11 , Hamideh Parhiz 12, Conrad O. Perera 13, Monica Pickholz 14,15, Milan Remko 16, Michele Saviano 17, Mariusz Skwarczynski 18, Yefeng Tang 19, Wojciech M. Wolf 2,*, Taku Yoshiya 20 , Janusz Zabrocki 5, Piotr Zielenkiewicz 21,22 , Maha AlKhazindar 4 , Vanessa Barriga 1, Konstantinos Kelaidonis 6, Elham Mousavinezhad Sarasia 9 and Istvan Toth 18,23,24 1 Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia; [email protected] (V.A.); [email protected] (J.M.); [email protected] (V.B.) 2 Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland 3 Department of Chemical Science, Faculty of Science, Universiti Tunku Abdul Rahman, Kampar 31900, Malaysia; [email protected] 4 Botany and Microbiology Department, Faculty of Science, Cairo University, Gamaa St., Giza 12613, Egypt; [email protected] (S.E.); [email protected] (M.A.) 5 Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland; [email protected] (K.K.); [email protected] (J.Z.) 6 NewDrug, Patras Science Park, 26500 Patras, Greece; [email protected] 7 Department of Physiology and Pharmacology,
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • The Direct Effects of the Angiotensin-Converting Enzyme
    European Journal of Endocrinology (2006) 154 355–361 ISSN 0804-4643 EXPERIMENTAL STUDY The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets Roberto Lupi, Silvia Del Guerra, Marco Bugliani, Ugo Boggi1, Franco Mosca1, Scilla Torri, Stefano Del Prato and Piero Marchetti Metabolic Unit, Department of Endocrinology and Metabolism, University of Pisa, Ospedale Cisanello, via Paradisa 2, 56100 Pisa, Italy and 1Transplant Unit, Department of Oncology, University of Pisa, Pisa, Italy, Menarini Ricerche SpA, Florence, Italy (Correspondence should be addressed to P Marchetti; Email: [email protected]) Abstract Objective: Data from prospective studies suggest a significant reduction in the risk of new diabetes from drug therapies containing angiotensin-converting enzyme (ACE) inhibitors. Since the renin–angio- tensin system (RAS) has been found locally in several tissues and cells, including pancreatic islets, we hypothesized that the positive metabolic effects of ACE inhibitors may be due to a beneficial action of these compounds on insulin-secreting b-cells. Design and methods: Isolated human pancreatic islets were studied after 24 h of incubation with 22.2 mmol/l glucose, with or without the presence in the incubation medium of 0.5–6.0 mmol/l zofe- noprilat or enalaprilat, ACE inhibitor drugs which differ by the presence of a sulphydryl or a carboxyl group in their structural formula. Functional and molecular studies were then performed to assess insulin secretion, redox balance, mRNA and protein expression. Results: Angiotensinogen, ACE and angiotensin type 1 receptor mRNA expression increased in islets cultured in high glucose; this was similarly prevented by the presence of either ACE inhibitor.
    [Show full text]
  • Healthcare Bulletin |
    CARDIOVASCULAR DISEASE MANAGEMENT | REVIEW Safety and Efficacy of the bi-Sulfydryl ACE-Inhibitor Zofenopril in the Management of Cardiovascular Disease Claudio Napoli, Department of General Pathology, Division of Clinical Pathology & Excellence Research Centre on Cardiovascular Disease Recieved 15/08/2009, Reviewed 21/08/2009, Accepted 27/08/2009 Keywords: ACE, zofenopril, atherosclerosis, acute myocardial infarction DOI:10.5083/ apjcm.20424906.05 ABSTRACT CORRESPONDENCE In the 1970s, pharmacological therapy interrupting the renin-angiotensin system was considered Claudio Napoli beneficial for patients with high-renin hypertension. Angiotensin-converting enzyme (ACE) Department of inhibitors proved to be effective not only in patients with high renin and elevated blood pressure, General Pathology, but also in many hypertensive patients with normal levels of plasma renin activity. ACE inhibitors are Division of Clinical Pathology used in a wide range of chronic illnesses such as atherosclerosis, hypertension, myocardial infarction, and Excellence Research Centre on Cardiovascular heart failure, diabetic complications, and stroke. To date, more than ninety controlled clinical trials Disease, evaluating the beneficial effects of 14 different ACE inhibitors were conducted. Moreover, data from 1st School of Medicine, experimental studies showed that ACE inhibitors can attenuate the development of atherosclerosis, II University of Naples, oxidative stress, and vascular inflammation in a wide range of species indicating that ACE inhibition Complesso S. Andrea also favourably affects the vasculature. More than fifteen years ago, the bi-sulfydryl ACE-inhibitor delle Dame, zofenopril has shown an excellent clinical safety and efficacy in patients with hypertension and in 80138 Naples, those with myocardial infarction. More recently, this compound exhibited a potent antioxidant and Italy.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Hydrogen Sulfide Accounts for the Peripheral Vascular Effects of Zofenopril Independently of ACE Inhibition
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della ricerca - Università degli studi di Napoli Federico II Cardiovascular Research (2014) 102, 138–147 doi:10.1093/cvr/cvu026 Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition Mariarosaria Bucci1†, Valentina Vellecco1†, Anna Cantalupo1†, Vincenzo Brancaleone2, Zongmin Zhou3, Stefano Evangelista4, Vincenzo Calderone5, Andreas Papapetropoulos3, and Giuseppe Cirino1* 1Department of Pharmacy, University of Naples ‘Federico II’, Via D. Montesano 49, Naples 80131, Italy; 2Department of Science, University of Basilicata, Potenza, Italy; 3Department of Pharmacy, Laboratory for Molecular Pharmacology, University of Patras, Patra, Greece; 4Menarini Ricerche spa, Firenze, Italy; and 5Department of Pharmacy, University of Pisa, Pisa, Italy Received 21 May 2013; revised 15 January 2014; accepted 25 January 2014; online publish-ahead-of-print 5 February 2014 Time for primary review: 53 days Aims Therapeutic use of sulfhydrylated inhibitor S-zofenopril has raised different hypotheses regarding the role played by its thiol group in the beneficial clinical effects exerted compared with other angiotensin-converting enzyme (ACE) inhibi- tors. Here, we investigated hydrogen sulfide (H2S) pathwayas accountable forextra-beneficialeffectsin vascular function. ..................................................................................................................................................................................... Methods Spontaneously hypertensive rat (SHRs) and control Wistar Kyoto (WKY) rats were treated with either S-zofenopril or and results enalapril in vivo. Aorta and carotid were harvested and ex vivo vascular reactivity to acetylcholine (Ach) and L-cysteine (L-cys) assessed. Cystathionine-b-synthase (CBS), cystathionine-g-lyase (CSE), and 3-mercaptosulfur-transferase (3MST) expression, as well as H2S levels, were evaluated in both vascular tissues.
    [Show full text]
  • Preclinical Profile of Zofenopril: an Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties
    Cardiovascular Drug Reviews Vol. 17, No. 2, pp. 115–133 © 1999 Neva Press, Branford, Connecticut Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties A. Subissi, S. Evangelista and A. Giachetti Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy. Key Words: Angiotensin-converting enzyme inhibitor—Cardioprotection—Hypertension— Sulfhydryl—Zofenopril. INTRODUCTION The discovery of captopril, the prototype of orally active angiotensin-converting en- zyme inhibitors (ACEIs), represented a major breakthrough in the treatment of cardio- vascular diseases. Currently, captopril has four important indications: hypertension, con- gestive heart failure, acute myocardial infarction, and diabetic nephropathy. After the discovery of captopril, several new ACEIs were developed and introduced into medical practice. These new ACEIs are neither chemically nor pharmacologically identical; they differ in their chemical structure, functional groups (sulfhydryl in captopril, carboxyl in enalapril, or phosphinyl in fosinopril), active moiety (some are prodrugs), potency, an- cillary pharmacology, and pharmacokinetics. These and other important characteristics differentiate ACEIs and influence their ability to inhibit the enzyme in various organs. Since ACEIs appear to work by inhibiting angiotensin-converting enzyme (ACE) in critical tissues, tissue selectivity is one of the most important properties that varies with the individual ACEIs. An important question is whether different tissue-selectivity profiles of ACEIs in ani- mal experiments are clinically relevant. Although the clinical relevance is not yet firmly established, the emerging evidence indicates that some differences among ACEIs are clinically significant (4,6,28,43). The latest ACE inhibitor to reach the European market is zofenopril calcium. By February 1999, it was registered in all 15 European Community countries.
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE)
    Angiotensin-converting Enzyme (ACE) Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure. www.MedChemExpress.com 1 Angiotensin-converting Enzyme (ACE) Inhibitors & Modulators Angiotensin 1-7 Benazepril (Angiotensin-(1-7); Ang-(1-7)) Cat. No.: HY-12403 Cat. No.: HY-B0093 Bioactivity: Angiotensin (1-7) inhibits purified canine angiotensin Bioactivity: Benazepril, an angiotensin converting enzyme inhibitor, which converting enzyme ( ACE) activity with an IC50 of 0.65 μM. is a medication used to treat high blood pressure. Purity: 99.61% Purity: >98% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in Water, Size: 1 g, 5 g 5 mg, 10 mg, 25 mg, 50 mg Benazepril hydrochloride Captopril (CGS14824A) Cat.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Zofenopril (calcium salt) Item No. 29525 CAS Registry No.: 81938-43-4 Formal Name: (4S)-1-[(2S)-3-(benzoylthio)- 2-methyl-1-oxopropyl]- 4-(phenylthio)-L-proline, hemicalcium salt Synonym: SQ 26991 S MF: C22H22NO4S2 • 1/2Ca FW: 448.6 S N Purity: ≥98% O O UV/Vis.: λmax: 238 nm O Supplied as: A solid • 1/2Ca2+ -O Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Zofenopril (calcium salt) is supplied as a solid. A stock solution may be made by dissolving the zofenopril (calcium salt) in the solvent of choice, which should be purged with an inert gas. Zofenopril (calcium salt) is slightly soluble in methanol. Description Zofenopril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor zofenoprilat.1 Zofenopril is hydrolyzed by cardiac esterases in vivo to form zofenoprilat. It inhibits ACE with an IC50 value of 0.9 nM in heart tissue homogenates and inhibits cardiac ACE activity in isolated perfused rat hearts. It reduces mean arterial blood pressure in two kidney-one clip renal hypertensive (2K-1C) rats and spontaneously hypertensive rats (SHRs) when administered at doses of 2.2, 6.6, and 22 mg/kg.2 Unlike the ACE inhibitor ramipril (Item No. 15558), zofenopril does not affect bronchoalveolar lavage fluid (BALF) levels of bradykinin 3 or prostaglandin E2 (PGE2; Item No. 14010) or increase coughing induced by citric acid in guinea pigs. References 1. Grover, G.J., Sleph, P.G., Dzwonczyk, S., et al.
    [Show full text]
  • Angiotensin II Type 1 Receptor (AT1R) Changes in Animal Model of Chronic Kidney Disease: Evaluation and Pharmacotherapy
    Angiotensin II Type 1 Receptor (AT1R) Changes in Animal Model of Chronic Kidney Disease: Evaluation and Pharmacotherapy By Basma Ismail Thesis submitted to the Faculty of Graduate and Posdoctoral Studies in partial fulfillment of the requirements for a doctoral degree in Cellular and Molecular Medicine. Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa © Basma Ismail, Ottawa, Canada, 2016 Basma Ismail Evaluation of AT1 receptor in chronic kidney disease ABSTRACT Cardiovascular complications represent the leading cause of death in chronic kidney disease (CKD) patients. Significant renal mass reduction induced by 5/6 subtotal nephrectomy (Nx) animal model leads to a chain of events that culminates in hypertension and CKD. The renin angiotensin (Ang) system (RAS) is known to be dysregulated, specifically Ang type 1 receptor (AT1R) plays a major role in development and progression of the disease. However, conflicting results have been reported on intrarenal AT1R levels, and the impact of antihypertensive drugs on RAS signaling is divergent. We hypothesize that PET imaging will be able to quantify kidney AT1R expression reliably in healthy and disease states. The broad objectives of this research project were: (i) to develop a positron emission tomography (PET) probe capable of detecting changes in the AT1R binding in the kidney; (ii) to elucidate the nature/temporal role of renal AT1R in Nx rat model of CKD; and (iii) to explore the predictive value of non-invasive PET imaging of AT1R to guide the use of antihypertensive therapy in preventing the progression of the disease. The novel selective AT1R PET radioligand 18 [ F]FPyKYNE-losartan was successfully used with PET in detecting renal AT1Rs at early and late stages of the CKD.
    [Show full text]